That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer.
Wharton's Jeremy Siegel just introduced a caveat to his perennially bullish outlook for the markets.
The market has nearly tripled in a little over five years. With each record, the temptation grows to take your winnings and flee.
Twitter stock is down 27 percent this year, but trader Steve Grasso thinks it's headed higher.
Get the best of CNBC in your inbox